Transient expansion of activated CD8+ T cells characterizes tuberculosis-associated immune reconstitution inflammatory syndrome in patients with HIV: A case control study

Journal of Inflammation (United Kingdom)

Volumn 10, Issue 1, 2013, Pages

  Espinosa, Enrique ^a   Romero Rodríguez, Dámaris P ^a   Cantoral Díaz, María Teresa ^a   Reyes Terán, Gustavo ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Activation; CD8 T cells; Highly active anti retroviral therapy (HAART); HIV 1; HIV 2; Human immunodeficiency virus (AIDS); Inflammation

Indexed keywords

ANTIRETROVIRUS AGENT; HLA DR ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOPATHOGENESIS; LYMPHOCYTE COUNT; MALE; MEMORY CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; TUBERCULOSIS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 84879056625     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-10-21     Document Type: Article

References (54)

1. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. Murdoch DM, Venter WD, van Rie A, Feldman C, AIDS Res Ther 2007 4 9 10.1186/1742-6405-4-9 17488505
2. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G, Drugs 2008 68 191 208 10.2165/00003495-200868020-00004 18197725
3. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. French MA, Clin Infect Dis 2009 48 101 107 10.1086/595006 19025493
4. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. Murdoch DM, Venter WD, Feldman C, van Rie A, AIDS 2008 22 601 610 10.1097/QAD. 0b013e3282f4a607 18317001
5. Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy. Oliver BG, Elliott JH, Price P, Phillips M, Saphonn V, Vun MC, Kaldor JM, Cooper DA, French MA, J Infect Dis 2010 202 1728 1737 10.1086/657082 20977362
6. d-Dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS. Porter BO, Ouedraogo GL, Hodge JN, Smith MA, Pau A, Roby G, Kwan R, Bishop RJ, Rehm C, Mican J, Sereti I, Clin Immunol 2010 136 42 50 10.1016/j.clim.2010.02.010 20227921
7. Biology of CCR5 and its role in HIV infection and treatment. Lederman MM, Penn-Nicholson A, Cho M, Mosier D, JAMA 2006 296 815 826 10.1001/jama.296.7.815 16905787
8. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. Funderburg N, Kalinowska M, Eason J, Goodrich J, Heera J, Mayer H, Rajicic N, Valdez H, Lederman MM, PLoS One 2010 5 13188 10.1371/journal.pone.0013188 20949133
9. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Blackmore TK, Manning L, Taylor WJ, Wallis RS, Clin Infect Dis 2008 47 83 e85 10.1086/592695 18840076
10. Prevention and treatment of the immune reconstitution inflammatory syndrome. Meintjes G, Lynen L, Curr Opin HIV AIDS 2008 3 468 476 10.1097/COH.0b013e3282fe6e84 19373007
11. Life-threatening exacerbation of Kaposi's sarcoma after prednisone treatment for immune reconstitution inflammatory syndrome. Volkow PF, Cornejo P, Zinser JW, Ormsby CE, Reyes-Teran G, AIDS 2008 22 663 665 10.1097/QAD. 0b013e3282f4f223 18317012
12. Elevated frequencies of highly activated CD4+ T cells in HIV + patients developing immune reconstitution inflammatory syndrome. Antonelli LR, Mahnke Y, Hodge JN, Porter BO, Barber DL, DerSimonian R, Greenwald JH, Roby G, Mican J, Sher A, Roederer M, Sereti I, Blood 2010 116 3818 3827 10.1182/blood-2010-05- 285080 20660788
13. Selective expansion of polyfunctional pathogen-specific CD4+ T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Mahnke YD, Greenwald JH, Dersimonian R, Roby G, Antonelli LRV, Sher A, Roederer M, Sereti I, Blood 2012 119 3105 3112 10.1182/blood-2011-09-380840 22219223
14. [Immune reconstitution inflammatory syndrome]. Breton G, Bull Acad Natl Med 2011 195 561 575 discussion 575 22292305
15. Immune reconstitution inflammatory syndrome: immune restoration disease 20 years on. French MAH, Med J Aust 2012 196 318 321 10.5694/mja12.10089 22432669
16. Risk factors for immune reconstitution inflammatory syndrome under combination antiretroviral therapy can be aetiology-specific. Espinosa E, Ormsby CE, Vega-Barrientos RS, Ruiz-Cruz M, Moreno-Coutino G, Pena-Jimenez A, Peralta-Prado AB, Cantoral-Diaz M, Romero-Rodriguez DP, Reyes-Teran G, Int J STD AIDS 2010 21 573 579 10.1258/ijsa.2010.010135 20975091
17. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC, Hamill RJ, AIDS 2005 19 399 406 10.1097/01.aids.0000161769.06158.8a 15750393
18. Immune reconstitution inflammatory syndrome: more answers, more questions. Shelburne SA, Montes M, Hamill RJ, J Antimicrob Chemother 2006 57 167 170 10.1093/jac/dki444 16354748
19. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ, Clin Infect Dis 2006 42 418 427 10.1086/499356 16392092
20. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ, Clin Infect Dis 2006 42 1639 1646 10.1086/503903 16652323
21. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, Elliott JH, Murdoch D, Wilkinson RJ, Seyler C, John L, van der Loeff MS, Reiss P, Lynen L, Janoff EN, Gilks C, Colebunders R, Lancet Infect Dis 2008 8 516 523 10.1016/S1473-3099(08)70184-1 18652998
22. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Meintjes G, Rangaka MX, Maartens G, Rebe K, Morroni C, Pepper DJ, Wilkinson KA, Wilkinson RJ, Clin Infect Dis 2009 48 667 676 10.1086/596764 19191655
23. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA, JAMA 2004 292 251 265 10.1001/jama.292.2.251 15249575
24. Current HIV treatment guidelines - an overview. Rathbun RC, Lockhart SM, Stephens JR, Curr Pharm Des 2006 12 1045 1063 10.2174/138161206776055840 16515485
25. Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: implications for multicenter clinical trials. The ACTG immunology advanced technology laboratories. Reimann KA, Chernoff M, Wilkening CL, Nickerson CE, Landay AL, Clin Diagn Lab Immunol 2000 7 352 359 10799445
26. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A, Nature 1999 401 708 712 10.1038/44385 10537110
27. Central memory and effector memory T cell subsets: function, generation, and maintenance. Sallusto F, Geginat J, Lanzavecchia A, Annu Rev Immunol 2004 22 745 763 10.1146/annurev.immunol.22.012703.104702 15032595
28. Memory in disguise. Sallusto F, Lanzavecchia A, Nat Med 2011 17 1182 1183 10.1038/nm.2502 21988989
29. Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets. Willinger T, Freeman T, Hasegawa H, McMichael AJ, Callan MF, J Immunol 2005 175 5895 5903 16237082
30. Chemokine receptor expression identifies Pre-T helper (Th)1, Pre-Th2, and nonpolarized cells among human CD4+ central memory T cells. Rivino L, Messi M, Jarrossay D, Lanzavecchia A, Sallusto F, Geginat J, J Exp Med 2004 200 725 735 10.1084/jem.20040774 15381728
31. Characterization of a subset of antigen-specific human central memory CD4+ T lymphocytes producing effector cytokines. Stubbe M, Vanderheyde N, Pircher H, Goldman M, Marchant A, Eur J Immunol 2008 38 273 282 10.1002/eji.200737611 18081039
32. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. Lederman MM, Calabrese L, Funderburg NT, Clagett B, Medvik K, Bonilla H, Gripshover B, Salata RA, Taege A, Lisgaris M, McComsey GA, Kirchner E, Baum J, Shive C, Asaad R, Kalayjian RC, Sieg SF, Rodriguez B, J Infect Dis 2011 204 1217 1226 10.1093/infdis/jir507 21917895
33. Plasma biomarkers in the prediction and diagnosis of tuberculosis- associated immune reconstitution inflammatory syndrome. French MA, Oliver BG, Elliott JH, Price P, AIDS 2011 25 1676 1677 10.1097/QAD.0b013e328349c6b5 21811106
34. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gammadelta T cells. Bourgarit A, Carcelain G, Samri A, Parizot C, Lafaurie M, Abgrall S, Delcey V, Vicaut E, Sereni D, Autran B, J Immunol 2009 183 3915 3923 10.4049/jimmunol.0804020 19726768
35. + T lymphocytes in control of Mycobacterium tuberculosis infection. Grotzke JE, Lewinsohn DM, Microbes Infect 2005 7 776 788 10.1016/j.micinf.2005.03.001 15823514
36. Mycobacterium tuberculosis genome-wide screen exposes multiple CD8 T cell epitopes. Hammond AS, Klein MR, Corrah T, Fox A, Jaye A, McAdam KP, Brookes RH, Clin Exp Immunol 2005 140 109 116 10.1111/j.1365-2249.2005.02751.x 15762882
37. + T-cell response in patients with pulmonary tuberculosis. Weichold FF, Mueller S, Kortsik C, Hitzler WE, Wulf MJ, Hone DM, Sadoff JC, Maeurer MJ, Genes Immun 2007 8 334 343 10.1038/sj.gene.6364392 17429413
38. + T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. Bruns H, Meinken C, Schauenberg P, Harter G, Kern P, Modlin RL, Antoni C, Stenger S, J Clin Invest 2009 119 1167 1177 10.1172/JCI38482 19381021
39. DAP10 contributes to CD8(+) T cell-mediated cytotoxic effector mechanisms during Mycobacterium tuberculosis infection. Hessmann M, Rausch A, Ruckerl D, Adams PS, Simon M, Gilfillan S, Colonna M, Ehlers S, Holscher C, Immunobiology 2011 216 639 647 10.1016/j.imbio.2010.09.010 21122940
40. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. Mogues T, Goodrich ME, Ryan L, LaCourse R, North RJ, J Exp Med 2001 193 271 280 10.1084/jem.193.3.271 11157048
41. CD4(+) T-cell subsets that mediate immunological memory to Mycobacterium tuberculosis infection in mice. Andersen P, Smedegaard B, Infect Immun 2000 68 621 629 10.1128/IAI.68.2.621-629.2000 10639425
42. Malignant and tuberculous pleural effusions: immunophenotypic cellular characterization. Aguiar LM, Antonangelo L, Vargas FS, Zerbini MC, Sales MM, Uip DE, Saldiva PH, Clinics 2008 63 637 644 10.1590/S1807-59322008000500012 18925324
43. Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection. Picker LJ, Hagen SI, Lum R, Reed-Inderbitzin EF, Daly LM, Sylwester AW, Walker JM, Siess DC, Piatak M, Wang C, Allison DB, Maino VC, Lifson JD, Kodama T, Axthelm MK, J Exp Med 2004 200 1299 1314 10.1084/jem.20041049 15545355
44. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS clinical trials group protocol 315. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St C, Kotzin BL, Fox L, Chiozzi MH, Leonard JM, Rousseau F, Wade M, Roe JD, Martinez A, Kessler H, J Infect Dis 1998 178 70 79 10.1086/515591 9652425
45. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. Lange CG, Lederman MM, Madero JS, Medvik K, Asaad R, Pacheko C, Carranza C, Valdez H, J Acquir Immune Defic Syndr 2002 30 33 40 12048361
46. + T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV, J Acquir Immune Defic Syndr Hum Retrovirol 1997 16 83 92 10.1097/00042560-199710010-00003 9358102
47. + T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV, J Acquir Immune Defic Syndr Hum Retrovirol 1998 18 332 340 10.1097/00042560-199808010-00004 9704938
48. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. Hsue PY, Hunt PW, Sinclair E, Bredt B, Franklin A, Killian M, Hoh R, Martin JN, McCune JM, Waters DD, Deeks SG, AIDS 2006 20 2275 2283 10.1097/QAD.0b013e3280108704 17117013
49. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis- associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. Elliott JH, Vohith K, Saramony S, Savuth C, Dara C, Sarim C, Huffam S, Oelrichs R, Sophea P, Saphonn V, Kaldor J, Cooper DA, Vun MC, French MA, J Infect Dis 2009 200 1736 1745 10.1086/644784 19874177
50. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. Wilkinson J, Cope A, Gill J, Bourboulia D, Hayes P, Imami N, Kubo T, Marcelin A, Calvez V, Weiss R, Gazzard B, Boshoff C, Gotch F, J Virol 2002 76 2634 2640 10.1128/JVI.76.6.2634-2640.2002 11861829
51. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. Bourboulia D, Aldam D, Lagos D, Allen E, Williams I, Cornforth D, Copas A, Boshoff C, AIDS 2004 18 485 493 10.1097/00002030-200402200-00015 15090801
52. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis- associated immune reconstitution inflammatory syndrome. Meintjes G, Wilkinson KA, Rangaka MX, Skolimowska K, van Veen K, Abrahams M, Seldon R, Pepper DJ, Rebe K, Mouton P, van Cutsem G, Nicol MP, Maartens G, Wilkinson RJ, Am J Respir Crit Care Med 2008 178 1083 1089 10.1164/rccm.200806-858OC 18755923
53. Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand. Tieu HV, Ananworanich J, Avihingsanon A, Apateerapong W, Sirivichayakul S, Siangphoe U, Klongugkara S, Boonchokchai B, Hammer SM, Manosuthi W, AIDS Res Hum Retroviruses 2009 25 1083 1089 10.1089/aid.2009.0055 19886838
54. HIV-1-related pleural tuberculosis: elevated production of IFN-gamma, but failure of immunity to Mycobacterium tuberculosis. Hodsdon WS, Luzze H, Hurst TJ, Quigley MA, Kyosiimire J, Namujju PB, Johnson JL, Kaleebu P, Okwera A, Elliott AM, AIDS 2001 15 467 475 10.1097/00002030-200103090-00005 11242143